Page last updated: 2024-11-07

carbachol and Supranuclear Palsy, Progressive

carbachol has been researched along with Supranuclear Palsy, Progressive in 1 studies

Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.

Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Warren, NM1
Piggott, MA1
Lees, AJ1
Perry, EK1
Burn, DJ1

Other Studies

1 other study available for carbachol and Supranuclear Palsy, Progressive

ArticleYear
Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: contrast with other dementias.
    Journal of chemical neuroanatomy, 2008, Volume: 35, Issue:3

    Topics: Alzheimer Disease; Atropine; Autoradiography; Carbachol; Cerebral Cortex; Dementia; Humans; Lewy Bod

2008